#ASCOAdvocacy is calling on OMB to revise & delay a proposed rule that would undermine merit-review research, devastate public scientific conversations, & allow agencies to terminate grants mid-stream. Full statement: https://bit.ly/4wx30q8

Prior authorization delays harm people w cancer. The #SeniorsAct, is a bipartisan bill that would help #FixPriorAuth in Medicare Advantage and improve pt care. Congress needs to act NOW. Tell your lawmakers to pass the Seniors Act: https://bit.ly/44xZ3G5 #ASCOAdvocacy

What an amazing, dynamic, supportive, powerful collection of women in oncology at @ascocancer.bsky.social Breakthrough in Singapore! #ascobt26

Excited to be in Singapore for @ascocancer.bsky.social Breakthrough with @herbloongmd.bsky.social Naoto Ueno, Beth Mittendorf, and Rebecca Dent!

Can precision screening work in low-resource settings? Dr. Nora Pashayan says yes! Her #ASCOBT26 keynote explores how risk-stratified questionnaires can optimize cancer screening without expensive lab tests, ideal in LMICs. Learn more: https://bit.ly/4eb6uIJ

Our LDP returns to the Asia Pacific region in 2027-28! 🌏 Expand your network, collaborate with regional peers, & build the skills needed to grow as a leader. 🗓️ Apply by August 17, 2026: https://bit.ly/4xg3zWG

Our new position statement outlines ways to expand eligibility, increase funding & expand community access for pediatric oncology clinical trials. Learn more: https://bit.ly/4v1q7J7 #ASCOAdvocacy

Cancer research awards for early career investigators from @binaytara.bsky.social - lung cancer, precision oncology, hematology, implementation science. binaytara.org/research-gra...

The story of GLP-1 drugs keeps getting bigger. First they transformed the treatment of diabetes. They upended the science — and culture — of weight loss. Now, studies are fueling optimism about their potential role in preventing and treating cancers.

The science around GLP-1 drugs and cancer is suddenly getting a lot more interesting

Studies released in recent weeks are fueling optimism — and fresh questions — about GLP-1 drugs' potential role in cancer prevention and treatment.

washingtonpost.com

Triple oral metronomic chemotherapy combined with ultra-low-dose immunotherapy may be a promising first-line treatment for patients in low-resource countries with recurrent or metastatic HNSCC, a trial suggested. #ASCO26 @jrgralow.bsky.social https://www.medpagetoday.com/meetingcoverage/asco/121557

Ultra-Low-Dose Immunotherapy May Benefit Cancer Patients in Low-Resource Countries

Regimen showed benefit in advanced head and neck cancer

medpagetoday.com

What’s the role of #GLP-1s in cancer care? Research presented at #ASCO26, examining real-world data shows GLP-1s may reduce metastatic progression of certain #obesity-related cancers: lung, breast, colorectal & liver. @jrgralow.bsky.social explains in this Science in Seconds. https://bit.ly/3Q5Ya3G

One more chance to connect with your people in person at a member-led Communities of Practice gathering at #ASCO26. Meet colleagues in your interest areas to collaborate, share expertise & build community. See today’s meetings: https://bit.ly/42LI0iM #HospitalOncCoP #SurvOncCoP #RAISECoP

5 speakers. 5 languages. 5 unforgettable stories. 🌍 The #ASCO26 Global Voices videos are live! Watch five unique personal stories from the global oncology community, captured in their native languages with English subtitles. Watch now: https://bit.ly/4f1SqSP

Short term fasting around chemotherapy administration linked to better outcomes in ovarian cancer #asco26 @ascocancer.bsky.social www.healio.com/news/hematol...

Short-term fasting linked to better outcomes among women with advanced ovarian cancer

CHICAGO — Fasting before and after chemotherapy may improve treatment response among women with high-grade serous ovarian cancer, according to findings presented at ASCO Annual Meeting.Study par...

healio.com

Use of GLP-1s in patients with four solid tumor types was significantly associated with lower rates of progression to metastatic disease over a 5-year period, a propensity score-matched analysis found. #ASCO26 @jrgralow.bsky.social https://www.medpagetoday.com/meetingcoverage/asco/121397

GLP-1s Linked to Lower Risk of Cancer Spread in Four Tumor Types

Accumulating evidence of possible benefit warrants randomized trials, experts say

medpagetoday.com

We’re pleased to announce our Featured Voices for #ASCO26! Get their expert insights into the science & ed sessions, what they view as practice changing & how they’ll bring what they’ve learned into the clinic. Follow & be a part of the conversation using the meeting hashtag. https://bit.ly/4uln3XV

If you haven’t yet registered to join us at this meeting, registration is still open! Register today: bit.ly/4uPXNcm

American Society of Clinical Oncology@ascocancer.bsky.social · 3mo ago

Abstract titles for 2026 ASCO Breakthrough are now live! Get a first look at the groundbreaking global research and practice-changing discoveries that will be discussed by international experts with deep regional knowledge: https://bit.ly/4udxJId #ASCOBT26

ASCO President Eric Small Honors The Impact of Volunteers @ascocancer.bsky.social @ericsmall.bsky.social oncodaily.com/voices/asco-... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

ASCO President Eric Small Honors The Impact of Volunteers - OncoDaily

ASCO President Eric Small Honors The Impact of Volunteers / ASCO, cancer, Eric Small, OncoDaily, Oncology

oncodaily.com

#ASCO26 is rapidly approaching - followed shortly afterwards by #ASCOBT26 in Singapore! Looking forward to science and networking with @ascocancer.bsky.social and the global community. Register by May 20 to secure the early registration discount! Join me there: asco.org/breakthrough

Check out the latest open-access ASCO Educational Book article by Common Sense Oncology fellow Dr. Sam Stevens and peers: "Innovation, Evidence, Compassion, and Hope: Delivering Outcomes That Matter". ascopubs.org/doi/full/10.... #CommonSenseOncology #CancerCare

Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: https://bit.ly/4mJlQGV

Check out the latest #TAPUR study paper in #JCOPO: Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Read the full article: https://bit.ly/4cVvaUU

Congrats Fidel Rubagumya on your new book “Beyond Cancer” with a forward by @lynnschuchter.bsky.social!

Proud to present the @ascocancer.bsky.social Congressional Champion for Cancer Care award to Representative Kim Schrier @repkimschrier.bsky.social (WA-08), the first pediatrician elected to Congress. Her leadership continues to pave the way for meaningful, long-term commitments to cancer care.

Terrific @csoncol.bsky.social meeting in Montreal. Fun dinner with “CSO OncoBabes” - Named by @eaeisenhauer.bsky.social. Also plenty of plaid flannel and poutine. @angiedemichele.bsky.social @winettevandergraaf.bsky.social

Advocating for Sustained Federal Investment in Cancer Research - Julie Gralow @jrgralow.bsky.social oncodaily.com/voices/julie... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Julie Gralow: Advocating for Sustained Federal Investment in Cancer Research - OncoDaily

Julie Gralow: Advocating for Sustained Federal Investment in Cancer Research / cancer, Julie Gralow, NCI, NIH, OncoDaily, Oncology

oncodaily.com

The draft guideline protocol for "Treatment of Patients with Invasive #CervicalCancer" is open for comments. Please review and submit your comments by April 7 to help shape final recommendations. Read & comment here: https://bit.ly/4sUHji8

Celebrating a decade of research. Join founding PI Dr. Richard Schilsky & TAPUR experts on May 12 for the Fourth Annual TAPUR Virtual Grand Rounds. Tune in to explore TAPUR’s decadelong impact & its future in clinical research.🧬 Register today: https://bit.ly/485rXza

New evidence-based recommendations for thyroid cancer systemic therapy are now available. Covering: ✅ Well-differentiated ✅ Differentiated high-grade ✅ Poorly differentiated ✅ Anaplastic & Medullary Read the full article: https://bit.ly/48jVCEV

ASCO Breakthrough 2026 to Convene Global Oncology Community in Singapore @cliffordhudis.bsky.social @jrgralow.bsky.social @ascocancer.bsky.social @ericsmall.bsky.social oncodaily.com/voices/asco-... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

ASCO Breakthrough 2026 to Convene Global Oncology Community in Singapore - OncoDaily

ASCO Breakthrough 2026 to Convene Global Oncology Community in Singapore / ASCO, ASCOBT26, cancer, Clifford Hudis, Elizabeth Mittendorf, Eric Small, Julie

oncodaily.com